Journal article
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial
N Wood, T Nolan, H Marshall, P Richmond, E Gibbs, K Perrett, P McIntyre
JAMA Pediatrics | AMER MEDICAL ASSOC | Published : 2018
Open access
Abstract
Importance: An alternative option to maternal vaccination to prevent severe pertussis in infants is vaccination at birth. Data are needed on the immunogenicity and safety of a birth dose of monovalent acellular pertussis (aP) vaccine. Objective: To compare IgG antibody responses to vaccine antigens at 6, 10, 24, and 32 weeks of age between newborn infants receiving the aP vaccine and hepatitis B vaccine (HBV) or HBV alone. Design, Setting, and Participants: A randomized clinical trial was conducted at 4 sites in Australia (Sydney, Melbourne, Adelaide, and Perth) between June 11, 2010, and March 14, 2013, among 440 healthy term (>36 weeks' gestation) infants aged less than 5 days at recruitme..
View full abstractGrants
Awarded by Murdoch Children's Research Institute
Funding Acknowledgements
Drs Wood and Marshall are supported by National Health and Medical Research Council (NHMRC) Career Development Fellowships APP1063629 (Dr Wood) and APP1084951 (Dr Marshall). Dr Perrett was supported by an NHMRC Early Career Fellowship (APP1054394) and a Murdoch Children's Research Institute Career Development Award. This study was supported by Australian NHMRC project grant 570756.